COMUNICADO: Nuevos datos apoyan la firma clínica única de Valdoxan(R) (y 2)

[1] Goodwin G et al, Agomelatine Prevents Relapse in Patients with Major Depressive Disorder Without Evidence of a Discontinuation Syndromw: A 24-Week Randomized, Double-Blind, Placebo-Controlled Trial. J. Clin. Psychiatry. 2009;70(8):1128-1137

[2] Stahl SM, Fava M, Trivedi MH, Caputo A, Shah A, Post A. Agomelatine in the Treatment of Major Depressive Disorder: An 8-Week, Multicenter, Randomized, Placebo-Controlled Trial J. Clin. Psychiatry. 2010;71(5):616-626

[3] Lemoine P, Guilleminault C, Alvarez E. Improvement in Subjective Sleep in Major Depressive Disorder With a Novel Antidepressant, Agomelatine: Randomized, Double-Blind Comparison With Venlafaxine. J. Clin. Psychiatry. 2007;68:1723-1732

[4] Kasper S, Hale A, Lemoine P, Quera Salva MA. Superior efficacy results of agomelatine in pooled analysis versus SSRI/SNRI. Abstract ECNP 2010

[5] Kennedy S, Rizvi S. Agomelatine in the treatment of major depressive disorder: potential for clinical effectiveness. CNS Drugs 2010 Review Article.

[6] Leproult R, Van Ondergergen A, L'Hermite-Baleriaux M, Van Cautert E, Copinschi G. Clin. Endocrinol. 2005;63:298-304

[7] Hale A, Corral R, Mencacci O, Saiz Ruiz J, Severo A, Gentil V. Superior efficacy of agomelatine vs fluoxetine in severe MDD patients: a randomised, double-blind study. J. Eur. College of Neuropsychopharmacol. 2009;19(suppl 3):S418

[8] Kasper S et al. Efficacy of the Novel Antidepressant Agomelatine on the Circadian Rest-Activity Cycle and Depressive and Anxiety Symptoms in Patients with Major Depressive Disorder: A Randomized, Double-Blind Comparison with Sertraline. J. Clin. Psychiatry. 2010;71(2):109-120

[9] Kennedy SH, Rizvi S, Fulton K, Rasmussen J. A Double-Blind Comparison of Sexual Functioning, Antidepressant Efficacy, and Tolerability Between Agomelatine and Venlafaxine XR. J Clin Psychopharmacol. 2008;28:329-333.

[10] Montgomery SA, Kennedy SH, Burrows GD, Lejoyeux M, Hindmarch I. Absence of discontinuation symptoms with agomelatine and occurrence of discontinuation symptoms with paroxetine: a randomized, double-blind, placebo-controlled discontinuation study. Int Clin Psychopharmacol. 2004;19:271-280

[11] Valdoxan(R) Summary of Product Characteristics

[12] http://www.who.int/mental_health/management/depression/definition/en/ (accessed 22 July 2010)

[13] WHO Europe, Mental health in the WHO European Region Fact sheet EURO/03/03, 8 September 2003

[14] Prevalence, burden and diagnosis - Chapter One, Page One, 5 April 2007

Para más información, contacte con: Natalie Fairbank, Tonic Life Communications (Tel. +44-20-7798-9906), natalie.fairbank@toniclc.com

WhatsAppFacebookTwitterLinkedinBeloudBluesky